


Ask a doctor about a prescription for VEREGEN 100 mg/g OINTMENT
Package Leaflet: Information for the User
Veregen 100 mg/g Ointment
Extract of green tea leaves
Read the package leaflet carefully before starting to use the medicine, as it contains important information for you.
Contents of the Package Leaflet
Veregen is a herbal medicine for exclusive use on the skin. Its active ingredient is an extract from green tea leaves. Veregen is used to treat genital warts (Condylomata acuminata) on the surface of the genitals (sex organs) and around the anus. Veregen is used in adults with a normally functioning immune system.
You should consult your doctor if your condition worsens or does not improve after 4-6 weeks of treatment.
Talk to your doctor before using Veregen.
Do not use Veregen
Warnings and precautions
Children and adolescents
Veregen is not recommended for use in children and adolescents under 18 years of age.
Using Veregen with other medicines
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines or if you have recently undergone other treatments for warts around the sex organs or anus. Veregen should not be used together with another treatment in the area of the warts. Veregen should not be used until your skin has completely healed after previous treatments.
Using Veregen with food and drinks
There are no interactions with food and drinks.
As a precaution to avoid interactions/adverse effects, Veregen should not be used with dietary supplements containing large amounts of green tea leaf extract.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.
Pregnancy
There are limited data on the use of Veregen in pregnant women. Reproductive studies in animals have shown toxic effects.
Therefore, as a precautionary measure, although exposure to epigallocatechin gallate (the main component of green tea) is expected to be low after skin application, the use of Veregen should be avoided during pregnancy (see section “3. How to use Veregen”).
Breastfeeding
It is unknown whether Veregen or its metabolites are excreted in breast milk, and therefore, it is unknown whether there is a risk to breastfed infants.
However, after applying the product to the skin of breastfeeding mothers, the risk of adverse effects in the breastfed infant is likely to be low.
Fertility
There is no evidence of any effect on fertility if you use Veregen as prescribed.
Driving and using machines
There are no available studies that demonstrate the effects on the ability to drive and use machines. However, it is unlikely that the treatment will have effects on the ability to drive or use machines.
Veregen contains isopropyl myristate and propylene glycol monopalmitostearate.
Veregen contains, among other ingredients, high amounts of isopropyl myristate (IPM), which may cause skin irritation and sensitization, and propylene glycol monopalmitostearate, which may cause skin irritation.
Follow exactly the administration instructions of this medicine as indicated by your doctor. In case of doubts, consult your doctor or pharmacist again.
The recommended dose is up to 0.5 cm of ointment (corresponding to 250 mg) for all warts together, applied three times a day (morning, noon, and night).
Use in children and adolescents(under 18 years of age)
Veregen is not approved for use in children and adolescents under 18 years of age.
Elderly
There is limited experience with the use of Veregen in elderly people.
Liver impairment
You should not use Veregen if your liver function is impaired (e.g., abnormal fluid retention in the abdomen, yellow skin due to liver problems).
If you use more Veregen than you should
You may experience more intense local adverse reactions (see sections “2. What you need to know before using Veregen” and “4. Possible side effects”).
Remove excess ointment with mild soap and water.
If you accidentally ingest the ointment, contact your doctor.
In case of overdose or accidental ingestion, consult the Toxicology Information Service. Phone: 915 620 420.
If you forget to use Veregen
Continue with the next dose when it is due. Do not apply a double dose to make up for forgotten doses.
If you stop using Veregen
It is possible that the warts will not be eliminated.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Most side effects of Veregen are due to its local action on the skin and occur at the site of the treated wart or in its surroundings. Many patients suffer from redness, itching, irritation, pain, or swelling. Mild reactions are normal and should decrease after the first few weeks of treatment. However, if the intensity of local skin reactions affects your daily activities or if blisters appear, consult your doctor. It may be necessary to interrupt treatment. Treatment can be resumed after the skin reaction has disappeared. In the case of local vesicular reactions, please consult your doctor.
If you experience severe local reactions that cause unacceptable discomfort, such as local inflammation/infection, open ulcer, swelling of the lymph nodes, or any other severe reaction (e.g., constriction of the foreskin or urethra, difficulty urinating, or intense pain), you should stop treatment and remove the ointment with warm water and mild soap, and consult your doctor immediately.
For the assessment of side effects, the following frequency convention was used:
Very common | May affect more than 1 in 10 people |
Common | May affect up to 1 in 10 people |
Uncommon | May affect up to 1 in 100 people |
Very common:
Common:
Uncommon:
Adverse reactions that were observed only with a higher dose ointment (Veregen 15%):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not store above 25°C.
Use within 6 weeks of first opening the tube.
Do not use this medicine after the expiry date which is stated on the tube or carton, after EXP. The expiry date is the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Veregen
The active ingredient is a green tea leaf extract. 1 g of ointment contains 100 mg of extract (as dry, refined extract) of Camellia sinensis(L.) O. Kuntze folium (green tea leaf) (24-56:1), corresponding to: 55-72 mg of (-)-epigallocatechin gallate
First extraction solvent: water.
The other ingredients are: white petrolatum (contains all-rac-α-tocopherol), white wax, isopropyl myristate, oleic acid, propylene glycol monopalmitostearate.
Appearance of the product and contents of the pack
Veregen is a smooth, brown ointment, free of sandy particles, available in 2 tube sizes: 15 g and 30 g.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
Exeltis Healthcare S.L.
Avda. de Miralcampo, 7
Polígono Industrial Miralcampo
19200 Azuqueca de Henares
Spain
Manufacturer:
C.P.M. ContractPharma GmbH
Frühlingsstraße 7
83620 Feldkirchen-Westerham
Germany
This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Austria: | Veregen 10% Salbe | Italy: | Veregen |
Belgium: | Veregen pommade | Latvia: | Veregen 100 mg/g ziede |
Bulgaria: | ??????? 10% ??? | Lithuania: | Veregen 100 mg/g tepalas |
Croatia: | Veregen 100 mg/g mast | Luxembourg: | Veregen 10% |
Cyprus: | Veregreen 10% Αλοιφ? | Netherlands: | Veregen 10%, zalf |
Czech Republic | Veregen | Poland: | Veregen |
Estonia: | Veregen | Portugal: | Veregen |
France: | VEREGEN 10%, pommade | Romania: | Veregen 100 mg/g unguent |
Germany: | Veregen 10% Salbe | Slovak Republic: | Veregen 100 mg/g mast |
Greece: | Veregreen 10%Αλοιφ? | Slovenia: | Veregen 100 mg/g mazilo |
Hungary: | Veregen 10% kenocs | Spain: | Veregen 100 mg/g pomada |
Ireland: | Catephen 10 % ointment | United Kingdom (Northern Ireland): | Catephen 10 % ointment |
Date of last revision of this package leaflet: 02/2022
"Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/"
The average price of VEREGEN 100 mg/g OINTMENT in November, 2025 is around 60.18 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for VEREGEN 100 mg/g OINTMENT – subject to medical assessment and local rules.